Premium
POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB OR OBINUTUZUMAB IN RELAPSED/REFRACTORY FL OR DLBCL: UPDATED RESULTS OF A PHASE 1B/2 STUDY
Author(s) -
Matasar M.,
Herrera A.F.,
Kamdar M.,
Mehta A.,
Assouline S.,
Fleury I.,
Kim T.M.,
Kim W.S.,
Bosch F.,
Radford J.,
Flowers C.R.,
Bu L.,
Hong W.,
Sehn L.H.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2438_144
Subject(s) - medicine , bendamustine , rituximab , neutropenia , obinutuzumab , refractory (planetary science) , phases of clinical research , diffuse large b cell lymphoma , antibody drug conjugate , gastroenterology , surgery , oncology , chemotherapy , lymphoma , immunology , antibody , monoclonal antibody , biology , astrobiology